X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indoco Remedies Fact Sheet, Indoco Remedies Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indoco Remedies Fact Sheet   (INDOCO)

Here is the latest financial fact sheet of Indoco Remedies. For more details, see the Indoco Remedies quarterly results and Indoco Remedies share price and chart. For a sector overview, read our pharmaceuticals sector report.

INDOCO REMEDIES Price History

Price Rs 173.6
Mkt Cap Rs m 15,997
Vol '000 8.6
P/E X 38.8
P/CF X 11.4
EPS (TTM) Rs 4.5
% ch % 1.8
No. of shares m 92.18
% ch week % -7.0
% ch 1-mth % -11.7
% ch 12-mth % -17.4
52 week H/L Rs 317.0/167.2
(As on Jul 20, 2018 03:37:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

INDOCO REMEDIES Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
INDOCO REMEDIES EQUITY SHARE DATA
High Rs83162378412360 
Low Rs5155131263249 
Sales per share (Unadj.) Rs68.579.593.0109.4119.0 
Earnings per share (Unadj.) Rs4.66.39.08.98.4 
Diluted earnings per shareRs4.66.39.08.98.4 
Cash flow per share (Unadj.) Rs7.29.614.115.515.2 
Dividends per share (Unadj.) Rs1.101.401.601.601.60 
Adj. dividends per shareRs1.101.401.601.601.60 
Dividend yield (eoy) %1.61.30.60.50.5 
Book value per share (Unadj.) Rs44.949.657.362.670.7 
Adj. book value per shareRs44.949.657.362.570.7 
Shares outstanding (eoy) m92.1592.1592.1592.1592.15 
Bonus/Rights/Conversions  FV2, B1:2---- 
Price / Sales ratio x1.01.42.73.12.6 
Avg P/E ratio x14.517.228.337.936.4 
P/CF ratio (eoy) x9.311.218.021.820.0 
Price / Book Value ratio x1.52.24.45.44.3 
Dividend payout %23.722.217.818.019.1 
Avg Mkt Cap Rs m6,1749,98923,43831,08728,083 
No. of employees `000NANANA5.76.0 
Total wages/salary Rs m1,0791,2951,4001,8192,167 
Avg. sales/employee Rs ThNMNMNM1,762.41,817.0 
Avg. wages/employee Rs ThNMNMNM318.0359.0 
Avg. net profit/employee Rs ThNMNMNM143.3127.7 
INDOCO REMEDIES INCOME DATA
Net Sales Rs m6,3087,3268,57010,08110,968 
Other income Rs m1518171640 
Total revenues Rs m6,3237,3448,58710,09711,007 
Gross profit Rs m9261,2041,6551,7041,565 
Depreciation Rs m237309471607633 
Interest Rs m21918910612462 
Profit before tax Rs m4867231,096989909 
Minority Interest Rs m0-1000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m58143267170139 
Profit after tax Rs m427580828819771 
Gross profit margin %14.716.419.316.914.3 
Effective tax rate %11.919.824.417.215.3 
Net profit margin %6.87.99.78.17.0 
INDOCO REMEDIES BALANCE SHEET DATA
Current assets Rs m2,7553,0463,8904,6465,725 
Current liabilities Rs m1,9932,0222,9263,6415,454 
Net working cap to sales %12.114.011.310.02.5 
Current ratio x1.41.51.31.31.0 
Inventory Days Days5455646062 
Debtors Days Days7469666872 
Net fixed assets Rs m3,5923,6944,0224,2965,307 
Share capital Rs m184184184184184 
"Free" reserves Rs m3,9504,3805,0935,5816,331 
Net worth Rs m4,1424,5725,2775,7656,516 
Long term debt Rs m2741381293791,323 
Total assets Rs m6,9197,2948,2039,40611,970 
Interest coverage x3.24.811.49.015.6 
Debt to equity ratio x0.1000.10.2 
Sales to assets ratio x0.91.01.01.10.9 
Return on assets %9.310.511.410.07.0 
Return on equity %10.312.715.714.211.8 
Return on capital %15.919.422.218.112.4 
Exports to sales %33.533.936.240.10 
Imports to sales %5.45.47.57.70 
Exports (fob) Rs m2,1162,4803,1014,0440 
Imports (cif) Rs m3433966437730 
Fx inflow Rs m2,1162,4803,1014,0444,507 
Fx outflow Rs m4455498191,0171,141 
Net fx Rs m1,6711,9312,2823,0273,366 
INDOCO REMEDIES CASH FLOW
From Operations Rs m 687 988 1,090 1,122 886 
From Investments Rs m -426 -410 -884 -1,107 -1,706 
From Financial Activity Rs m -244 -590 -199 -16 1,316 
Net Cashflow Rs m 17 -12 7 -1 497 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 59.2%
Foreign collaborators 0.0%
Indian inst/Mut Fund 12.5%
FIIs 6.0%
ADR/GDR 0.0%
Free float 22.4%
Shareholders 12,805
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF 166, Indoco House, CST Road, kalina, Santacruz (E), Mumbai - 400 098
E-MAIL sunil.joshi@indoco.com WEB www.indoco.com
TELEPHONE (022) 2654 1851 FAX (022) 2652 3067
SECTOR MISCELLANEOUS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
AUDITOR Patkar & Pendse
CHM: Suresh G. Kare (MD) COMP SEC: Sunil D. Joshi YEAR OF INC: 1945 BSE CODE: 532612 FV (Rs): 2 DIV YIELD (%): 0.9

More Miscellaneous Company Fact Sheets:   PANACEA BIOTECH  MERCK LTD  FDC LTD.  SHASUN PHARMA  LUPIN LTD  

Compare INDOCO REMEDIES With:   PANACEA BIOTECH  MERCK LTD  FDC LTD.  SHASUN PHARMA  LUPIN LTD  

Compare INDOCO REMEDIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; IT Stocks Lead Gains(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day in above the dotted line.

Views on news

INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3% (Quarterly Result Update)

Jun 19, 2018 | Updated on Jun 19, 2018

For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

ICICI Pru Mutual Fund Tarakki Karega! - The Unethical Way?(Outside View)

Jul 11, 2018

PersonalFN explains how ICICI Prudential Mutual Fund flouted the norms of related party transactions while subscribing to the IPO of ICICI Securities.

PPF v/s Mutual Funds: Which Is Better?(Outside View)

Jul 10, 2018

PersonalFN highlights the key points of distinction between PPF and mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS